Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV001574783 | SCV001801658 | uncertain significance | not provided | 2019-04-15 | criteria provided, single submitter | clinical testing | Has not been previously published as pathogenic or benign to our knowledge; Not observed at a significant frequency in large population cohorts (Lek et al., 2016); In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function |
Fulgent Genetics, |
RCV002495920 | SCV002787105 | uncertain significance | Intervertebral disc disorder; Marshall syndrome; Stickler syndrome type 2; Fibrochondrogenesis 1; Hearing loss, autosomal dominant 37 | 2021-08-12 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001574783 | SCV003019077 | likely benign | not provided | 2024-11-03 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV004536209 | SCV004725662 | uncertain significance | COL11A1-related disorder | 2024-02-13 | no assertion criteria provided | clinical testing | The COL11A1 c.3068C>A variant is predicted to result in the amino acid substitution p.Ala1023Glu. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.00088% of alleles in individuals of European (Non-Finnish) descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |